44 results about "Asthma model" patented technology

The invention belongs to the technical field of biology, and relates to an allergic asthma model, in particular to application of chitosan serving as immuno-adjuvant in preparing a mouse allergic asthma model. According to the application, the mouse allergic asthma model prepared by applying chitosan serving as immuno-adjuvant is subjected to airway responsiveness, lung tissue pathological examination and inflammation marker inspection, and results indicate that the mouse allergic asthma model prepared by applying chitosan serving as immuno-adjuvant is remarkably superior to a conventional immuno-adjuvant prepared asthma model in airway eosinophilic inflammation, airway responsiveness and airway inflammatory cytolines and other aspects. The chitosan has low price and rich sources; and the mouse asthma model by using chitosan as immuno-adjuvant is remarkably superior to a traditional adjuvant, and has the advantages of simple method, low cost, good reproducibility and the like.

We describe for the first time that andrographolide dirivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-kappa B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.

The invention belongs to the pharmaceutical field, relates to a novel medicinal use of calycosin-7-glucoside and especially relates to a use of calycosin-7-glucoside in preparation of drugs for treating asthma and especially for treating allergic asthma. The results of an in-vivo animal experiment and an in-vitro CD4+T cell culture experiment show that calycosin-7-glucoside has effects on an ovalbumin-induced mouse asthma model and CD4+T cells isolated from spleen, and can significantly reduce airway hyperresponsiveness of asthmatic mice, inhibit airway inflammation, reduce the number of inflammatory cells in an alveolar lavage fluid, inhibit chemokine secretion, promote Th1 cell differentiation, inhibit IL-17A, promote IFN-gamma and IL-10 secretion and inhibit NF-kappa B activation. The calycosin-7-glucoside can be used as a single ingredient for preparation of drugs for treating asthma or allergic asthma.

An imageable rodent model for asthma is described. The invention provides a rodent model for asthma wherein a rodent is provided with fluorescently labeled lymphocytes sensitized to an allergen which can be monitored after inducing an asthmatic response by the allergen. Methods to monitor trafficking of the fluorescently labeled cells in the rodent model for asthma are provided. Methods to determine the effectiveness of candidate drugs that regulate asthmatic responses using the rodent asthma model are also provided.

The invention provides medicine for treating asthma. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the bronchial hyperresponsiveness of a mouse asthma model can be effectively lowered, the tracheospasm can be relieved, and airway pressure-time index (APTI) is 726-880 per second centimeter water column; the inflammation in the lung can be treated effectively, inflammatory cell infiltration can be reduced, and the percentage of eosinophilic granulocyte is 14.6-16.6%; the gamma-interferon (IFN-gamma) and antibody which are capable of inhibiting asthmatic attack can be increased, and the contents of interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13) which can induce the asthma can be lowered; the medicine is safe, efficient, free of side effect, quick in action during asthma preventing and treatment, capable of relieving chest distress and short of breath and evident in curative effect on the asthma.

A physical signs monitor with acoustic sensor for the asthma model of mouse features that a medical stethoscope is used as the sensing element to acquire the cardiac pulse wave of the mouse when it has an asthma attack for quantitatively analyzing the variation of its physical signs. Said monitor is composed of asthma exciter, mouse to be tested, asthma sign observing cabin, acoustic sensor, computer and sound wave amplifier.

The invention belongs to the field of biomedicine, relating to a method for establishing a chronic obstructive pulmonary disease superposition asthma model. By adopting a combined method of Drip endotoxin and smoke in trachea and egg albumin sensitization inspiration, the invention has reliable evaluation on aspects of lung tissue pathology, bronchial reactivity, serum cytokine, hypothalamus-hypophysis-adrenal axis and the like. The result of comparison with the pure chronic obstructive pulmonary disease or asthma model shows that the chronic obstructive pulmonary disease superposition asthma model has the characteristic change of the chronic obstructive pulmonary disease or asthma and weakens or intensifies the charateristic pathologic physiological changes. The invention has the advantages of simple preparation and good reliability and repetitiveness, and meets the disease pathologic physiological characteristics of the chronic obstructive pulmonary disease merger asthma, and can be used for the research of pathogenic mechanisms, prevention and treatment, and the like of the chronic obstructive pulmonary disease merger asthma.

The invention belongs to the technical field of medicines, and particularly relates to new application of guanosine, in particular to new application of guanosine in preparation of medicines for treating asthma or inhibitors of MAPK, NF-kappa B and STAT3. The invention aims to solve the problem that safer and more effective asthma treatment medicines need to be developed urgently in the prior art.It is found that in an in-vitro THP-1-derived macrophage inflammation model, guanosine inhibits generation of a proinflammatory factor IL-6 by inhibiting activation of MAPK and NF-kappa B; in an asthma mouse model, guanosine reduces OVA-IgE of mouse plasma, reduces generation of IL-4, IL-6 and IL-13, relieves airway high reactivity, and relieves lung tissue cell infiltration, airway inflammationand collagen deposition. In addition, the expression levels of p-p38 MAPK, p-p65 NF-kappa B, p-I kappa B alpha and p-STAT3 proteins in lung tissues of mice in a guanosine treatment group are obviouslylower than those in an asthma model group. Therefore, the invention provides application of guanosine in preparation of a p38 MAPK inhibitor, a p65 NF-kappa B inhibitor, an STAT3 inhibitor or an asthma treatment drug.

The invention discloses a small animal smoke inhalation microenvironment preparation system, which belongs to the technical field of biological and environmental medicine research and scientific research instruments, and is used for simulating a respiratory inhalation microenvironment, and preparing small animal respiratory system disease models including a chronic obstructive pulmonary disease model, an asthma model, a bronchial inflammation model, a PM2.5 inhalation injury model and a model antigen or drug inhalation injury model. The small animal smoke inhalation microenvironment preparation system is characterized by comprising a microenvironment box body, a main control box, a model preparation device, and an air exhaust device. During operation, smoke or air containing PM2.5 or containing antigen (or drug) generated in the model preparation device is injected into the microenvironment box body by means of an injection pump, real-time monitoring is realized by means of a measurement and control circuit, and a microenvironment in the microenvironment box body is fed back and regulated in real time according to a set limit value. The inhalation microenvironment prepared by the small animal smoke inhalation microenvironment preparation system has the advantages of precise index control, high stability, high repeatability and the like, is multi-purpose, and effectively saves the experimental costs of the instrument and equipment.

The invention belongs to the technical field of medicines, and in particular discloses an application of apocynin nitrone in preparing a medicine for preventing and treating asthma. According to the invention, an OVA (ovalbumin) induced mouse asthma animal model, effects of the apocynin nitrone on resisting inflammation, resisting oxidation and relaxing trachea are researched by virtue of such research methods as an integral animal experiment, an isolated trachea experiment and the like. Based upon test results, the apocynin nitrone can obviously improve lung tissue inflammation of an asthma model mouse and subsequent lung tissue injury, inhibit the generation of inflammatory cell factors and reduce a lung wet / dry weight ratio and a lung penetration index. The apocynin nitrone can improve levels of superoxide dismutase and glutathione in lung tissue homogenate, reduce level of a lipid peroxidation product, namely malonaldehyde, and improve a lung oxidative stress state. The apocynin nitrone can reduce smooth muscle tension of the isolated trachea and improve tracheospasm. The apocynin nitrone provided by the invention, as an active ingredient, can be used for preparing a pharmaceutical composition for preventing and treating the asthma in the combination with a pharmaceutically acceptable carrier or excipient.

The invention discloses a pharmaceutical composition of vesalium and medical application thereof. The pharmaceutical composition of vesalium contains vesalium and a novel-structure natural product compound (I). The glibenclamide and compound (I) can restore the serum indexes of the kidney-qi deficiency asthma model to normal and has the function of treating kidney-qi deficiency asthma when being independently used. The combination of the vesalium and compound (I) further enhances the treatment effects, and can be developed into drugs for treating the kidney-qi deficiency asthma. Compared with the prior art, the pharmaceutical composition has outstanding substantial characteristics and marked progress.

The invention belongs to the field of biotechnology and discloses application of trichosanthin in preparing an allelgic asthma model of mice, wherein the trichosanthin can exert functions without the assistance of an adjuvant. The invention also discloses an allelgic asthma disease model of the mice which is induced by the trichosanthin. An allelgic asthma animal model established by the invention has typical characteristics of an allelgic asthma disease, and can well simulate the generation and development of allelgic asthma in vivo. At the same time, the animal model can also be applied to screening medicines against the allelgic asthma.

The invention provides a building method of mouse asthma model sensitized by humulus pollen. The building method includes following steps: 1, sensitizing: subcutaneously injecting 200ul of humulus pollen sensitizing liquid behind the neck of a BALB / c mouse on the first day, the eighth day and the fifteenth day respectively; 2, exciting: enabling the mouse to inhale 1ug / ul of humulus pollen proteinextract through atomization for 30min each day for 7 days consecutively. The humulus pollen protein extract is used to perform subcutaneous injection sensitizing and atomization exciting on the BALB / c mouse, and the mouse asthma model sensitized by the humulus pollen is built successfully. The model mouse can well simulate typical features of human asthma caused by humulus pollen sensitizing. Themodel is about to provide a good platform for people to study pathogenesis of human asthma caused by humulus pollen sensitizing and to explore new treatment methods.

The invention discloses a traditional Chinese medicine composition for preventing and treating swine asthma, which comprises the following components in parts by weight: 25-40 parts of aster, 15-28 parts of peccary, 10-20 parts of bitter almond, and 8-15 parts of cortex mulberry , 10-20 parts of loquat leaves, 8-20 parts of Houttuynia cordata. The traditional Chinese medicine composition of the present invention has a very high cure rate to swine asthma. Through the observation of the curative effect on the swine asthma model of artificial disease, the high and medium dose groups of the tested drug have the effect on the curative effect of swine asthma and the weight gain of pigs. Obviously, it is completely suitable for the prevention and treatment of swine asthma.

The invention relates to a method for building an allergen-specific immunotherapy asthma model and belongs to the biotechnology field. The method comprises the steps of firstly sensitizing, then carrying out large dose allergen immunotherapy and finally stimulating and producing asthma symptoms. The method provided by the invention can realize an allergen immunotherapy asthma model with the same effect with the traditional therapy model (sensitization-stimulation-allergen immunotherapy), and a research period for building the asthma model is shortened at the same time.

The invention relates to the field of a protein drug, and particularly discloses novel use of S100 calcium binding protein A11 for preparation of a drug for relaxing airway smooth muscle, and a drug preparation containing the protein. The invention discloses a novel function of the S100 calcium binding protein A11 for relaxing the airway smooth muscle. The airway smooth muscle can be obviously relaxed by the S100A11; the airway resistance of an asthma model rat is reduced, so as to play a role of treatment of asthma. The S100 calcium binding protein A11 can be applied to treatment of an asthma disease and preparation of a drug for treating asthma, and is applied to the quality of the asthma disease in a form of an injection or spray. Therefore, the S100 calcium binding protein A11 has the advantages of being safe, effective and stable to use and the like.

The invention relates to the field of a protein medicine, and in particular discloses application of S100 calcium binding protein A8 in preparation of an airway smooth muscle dilating medicine and a pharmaceutical preparation containing the protein. The invention discloses a new function of S100 calcium binding protein A8 for dilating airway smooth muscle; S100A8 can significantly dilate the airway smooth muscle and reduce airway resistance of an asthma model rat so as to treat asthma; S100A8 is applicable to treatment of asthma disease and preparation of an asthma treating medicine; S100A8 is used for treating the asthma disease in a form of injection or spray, and is safe to use, effective and stable.

The invention discloses application of a perilla leaf extract to preparation of a medicament for treating and / or preventing asthma. The perilla leaf extract disclosed by the invention has a reversingeffect on the lung inflammation pathological injury of an asthma model mouse; generation of inflammatory cytokines of TNF-alpha, IL-1beta and the like in Bronchoalveolar Lavage Fluid (BALF) of the model mouse can be obviously inhibited; and the total number of leukocytes and the recruitment of lymphocytes and eosinophilic granulocyte in the BALF of the model mouse are obviously inhibited. The asthma effect of the model mouse is obviously improved.

A method for treating a disease is provided. The method includes steps of: providing a subject in need thereof; and administering one selected from a group consisting of KMUPS compound represented by formula I, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage from 1 to 2.5 milligram per kilogram of body weight,wherein R2 and R4 are each selected independently from a group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group and a halogen atom.

Compositions comprising oligonucleotides which are specifically hybridizable with nucleic acids encoding cellular adhesion molecules intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. A series of double stranded RNA molecules targeting human ICAM-1 were designed and inhibition of RNA was measured. Oligonucleotides targeted to ICAM were effective in reducing airway hyperresponsiveness in mouse and monkey asthma models.

The invention relates to an analysis method of hyssopus officinalis volatile oil and application of the hyssopus officinalis volatile oil in preparation of a medicine for treating hormone-resistant asthma, which comprises qualitative and relative quantitative analysis of chemical components of the hyssopus officinalis volatile oil, construction of a hormone-resistant asthma model and grouped administration. The influence of the hyssopus officinalis volatile oil on the number of inflammatory cells in alveolar lavage fluid and peripheral blood of a mouse with the hormone-resistant asthma is researched, and the influence of the hyssopus officinalis volatile oil on the concentration of interleukin-17 (IL-17) and granulocyte colony stimulating factor (G-CSF) in BALF and lung tissues of the mouse with the hormone-resistant asthma is researched. The influence of the hyssopus officinalis volatile oil on pathological changes of lung tissues of mice with hormone-resistant asthma is studied, and the chemical components of the hyssopus officinalis volatile oil and the pharmacological action of the hyssopus officinalis volatile oil for treating the hormone-resistant asthma are integrally evaluated according to the studies. The hyssopus officinalis volatile oil has great significance in new drug research and clinical application of the hyssopus officinalis volatile oil for treating the hormone-resistant asthma.

The invention discloses a method for detecting influences of attenuation bacillus calmette-guerin to asthma. The method comprises the following steps of: establishing asthma models of animals, inoculating bacillus calmette-guerin many times, and detecting the expression of lung tissue TLR4 (toll-like receptor 4) of the small animals by western blotting. According to the method for detecting influences of attenuationbacillus calmette-guerin to asthma of the invention, the influences of attenuation bacillus calmette-guerin to asthma are as follows: the therapeutic effects of the bacillus calmette-guerin are relative to the enhancement of the TLR4 (toll-like receptor 4) of the lung tissue, so that the attenuation bacillus calmette-guerin can play an important function in treating the asthma.

The invention belongs to the technical field of medicine application, and particularly discloses application of Fuganlin oral liquid in preparation of an anti-asthmatic and anti-inflammatory medicinefor preventing and / or treating asthma. The Fuganlin oral liquid provided by the invention has an obvious improvement effect on an immature rat asthma model induced by dust mites. Specifically, the Fuganlin oral liquid has inhibition effects on respiratory system resistance and respiratory system elasticity increase of dust mite-induced immature rats, and has an obvious inhibition effect on His content increase of dust mite-induced immature rats; and pathological examinations find that the Fuganlin oral liquid has good improvement effects on inflammatory cell infiltration and perivascular edemain lung tissues of dust mite-induced immature rats. Through pharmacodynamic tests and pathological examinations, the Fuganlin oral liquid can achieve symptomatic and supportive treatment and providereference for medicine new application clinical research, with good clinical application and popularization value.

The invention discloses the application of rosmarinic acid in the preparation of medicines for treating asthma, establishing mouse asthma models through ovalbumin induction, and confirming the effect of rosmarinic acid in treating asthma. The use of rosmarinic acid to treat asthma has the advantages of low toxicity, small side effects, and good curative effect.

The invention provides a biological peptide for treating asthma and application of the biological peptide. The invention also relates to a preparation method and application of the polypeptide and a pharmaceutical composition containing the polypeptide. The polypeptide disclosed by the invention has the advantages of small molecular weight, low production cost, good water solubility, good stability, long half-life period, small immunogenicity, low toxic and side effects, strong tissue penetrability and the like; and moreover, the research on an OVA-induced asthma mouse model shows that the biological peptide has remarkable functions of preventing, treating and / or relieving asthma.

The invention discloses application of arenobufagin in preparing a drug for preventing / treating an asthmic disease. Experiments prove that the arenobufagin can lower inflammatory cell infiltration andairway mucus hypersecretion in asthma model mouse lung tissues. The arenobufagin can exert the effect of treating asthma by inhibiting expressions of Eotaxin, IL-13 and IL-8 in a bronchoalveolar lavage fluid. The arenobufagin has an application prospect of treating the asthmic disease.

The invention discloses use of a small molecule compound aminoxyacetic acid in preparing a medicine for treating asthma. A mouse asthma model is established by using a sputum allergen, the mice are divided into a control group, an asthma group and an asthma intervention group, and the airway resistance, the pathological section, and the number of inflammatory cells in the bronchoalveolar lavage fluid are used to determine the severity of the disease in mice. The intervention of aminooxyacetic acid in the present invention can increase the proportion of Foxp3<+>Treg cells in the hilar lymph nodes, and can improve the severity of asthma, which is manifested by a decrease in pulmonary allergic inflammation, comprising a reduction in infiltration of inflammatory cells around the bronchi and adecrease in the proliferation of goblet cells, as well as eosinophils, lymphocytes and neutrophils in BALFs. In addition, the airway resistance of AOA-treated mice is significantly lower than that ofthe asthma group. The AOA of the present invention can be used as a potential drug for the treatment of asthma.